Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study

Currently, it has not been satisfactorily established, whether modern low-osmolality iodinated contrast agents (ICAs) used in computed tomography (CT) studies are a risk factor for exacerbation of myasthenic symptoms. The rate of acute adverse events as well as delayed clinical worsening up to 30 da...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2017-06, Vol.264 (6), p.1209-1217
Main Authors: Rath, Jakob, Mauritz, Matthias, Zulehner, Gudrun, Hilger, Eva, Cetin, Hakan, Kasprian, Gregor, Auff, Eduard, Zimprich, Fritz
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Cohort analysis
Cohort Studies
Contrast agents
Contrast Media - therapeutic use
Disease Progression
Female
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Myasthenia Gravis - diagnostic imaging
Myasthenia Gravis - metabolism
Neurology
Neuroradiology
Neurosciences
Original Communication
Studies
Time Factors
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Currently, it has not been satisfactorily established, whether modern low-osmolality iodinated contrast agents (ICAs) used in computed tomography (CT) studies are a risk factor for exacerbation of myasthenic symptoms. The rate of acute adverse events as well as delayed clinical worsening up to 30 days were analyzed in 73 patients with confirmed myasthenia gravis (MG) who underwent contrast-enhanced CT studies and compared to 52 patients who underwent unenhanced CT studies. One acute adverse event was documented. 12.3% of MG patients experienced a delayed exacerbation of symptoms after ICA administration. The rate of delayed severe exacerbation was higher in the contrast-enhanced group. Alternative causes for the exacerbation of MG-related symptoms were more likely than ICA administration in all cases. ICA administration for CT studies in MG patients should not be withheld if indicated, but patients particularly those with concomitant acute diseases should be carefully monitored for exacerbation of symptoms.
ISSN:0340-5354
1432-1459
DOI:10.1007/s00415-017-8518-8